Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held on June 6, 2023. The registrant is Ocuphire Pharma, Inc. (trading symbol: OCUP), a Delaware corporation. Note: The request metadata referenced "Opus Genetics, Inc.," but the filing text explicitly identifies the company as Ocuphire Pharma, Inc.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Voting Results
The filing details the outcomes of three proposals voted upon by stockholders. A total of 11,228,343 shares were present, representing approximately 53.60% of outstanding shares.
- Proposal 1 (Election of Directors): Six directors were elected to one-year terms. All nominees received a majority of votes cast, though significant votes were withheld for Cam Gallagher and Richard Rodgers.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Ernst & Young, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Proposal 3 (Say-on-Pay Frequency): Stockholders approved an advisory vote on executive compensation frequency of "every year."
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors. The primary operational outcome is the Board's determination to conduct annual advisory votes on executive compensation based on the stockholder vote.
Key Facts for Investor Verification
- Verify the correct company identity: The filing is for Ocuphire Pharma, Inc., not Opus Genetics, Inc.
- Confirm the tenure of the newly elected directors, which is one year until the 2024 annual meeting.
- Note the high number of broker non-votes (5,087,873) for the director election, indicating shares held by brokers that did not receive voting instructions.
- Review the significant vote withholding for directors Cam Gallagher and Richard Rodgers compared to other nominees.
- Confirm that the company will now hold annual say-on-pay votes as mandated by the stockholder advisory result.